Osugacestat

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameOsugacestat
Drug Alias NameAL-101(BMS)BMS-906024BM-0018
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-secretase inhibitorsCathepsin B inhibitors
TargetsGamma-secretaseCathepsin B
Therapy Area/IndicationsTriple Negative Breast NeoplasmsCarcinoma, Adenoid CysticPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb CompanyGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesAyala Pharmaceuticals IncImmunome Inc
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsCarcinoma, Adenoid Cystic
Inactive IndicationsTriple Negative Breast NeoplasmsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia